Bay City Capital

Portfolio Co Investors 2026 for Bay City Capital: investors, rounds, and co-investor patterns from StartupFundraising.com research, updated for 2026.

Bay City Capital accounts for 4 tracked companies with verified cap-table data, 4 of which disclose round sizes totalling $781M. The median disclosed raise is $200M, and the largest is Merus at $500M, ahead of Xeris Pharmaceuticals ($200M) and Kezar Life Sciences ($73M).

The names that recur most often on these co-invested cap tables are Bay City Capital (4 companies), LSP (Life Sciences Partners) (1 company), Johnson & Johnson Innovation (1 company), Pfizer Venture Investments (1 company), Novartis Venture Fund (1 company), Redmile Group (1 company). By latest disclosed round, the market skews IPO (2), Series B (1), Post IPO (1).

Best funded Bay City Capital companies

  1. Merus — $500M (latest: IPO)
  2. Xeris Pharmaceuticals — $200M (latest: IPO)
  3. Kezar Life Sciences — $73M (latest: Series B)
  4. Sunesis Pharmaceuticals — $7.7M (latest: Post IPO)

Bay City Capital — related firms and companies (47)

Bay City Capital alternatives · All research reports